beta-lapachone has been researched along with Cardiotoxicity in 1 studies
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase
beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nazari Soltan Ahmad, S | 1 |
| Sanajou, D | 1 |
| Kalantary-Charvadeh, A | 1 |
| Hosseini, V | 1 |
| Roshangar, L | 1 |
| Khojastehfard, M | 1 |
| Haiaty, S | 1 |
| Mesgari-Abbasi, M | 1 |
1 other study available for beta-lapachone and Cardiotoxicity
| Article | Year |
|---|---|
β-LAPachone ameliorates doxorubicin-induced cardiotoxicity via regulating autophagy and Nrf2 signalling pathways in mice.
Topics: AMP-Activated Protein Kinases; Animals; Antibiotics, Antineoplastic; Antioxidants; Autophagy; Cardio | 2020 |